Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Urine miRNA transcriptome of prostate cancer patients [Discovery cohort]

ABSTRACT: Urine miRNA transcriptome of prostate cancer patients [Discovery cohort]

PROVIDER: PRJNA412691 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Urine miRNA transcriptome of prostate cancer patients [Discovery cohort]

Project description:Intra-individual stability of the urine miRNA transcriptome was examined by investigating longitudinal changes over time in a cohort of patients with localized prostate cancer. Using training and validation cohorts, urinary miRNA biomarkers are characterized and validated their utility to identify aggressive prostate cancer.

2019-10-24 | GSE104431 | GEO

Urine miRNA transcriptome of prostate cancer patients [Validation cohort]

2019-10-24 | GSE104430 | GEO

Urine miRNA transcriptome of prostate cancer patients [Training cohort]

2019-10-24 | GSE104429 | GEO

Urine miRNA transcriptome of prostate cancer patients [Validation cohort]

Project description:Urine miRNA transcriptome of prostate cancer patients [Validation cohort]

| PRJNA412692 | ENA

Urine miRNA transcriptome of prostate cancer patients [Training cohort]

Project description:Urine miRNA transcriptome of prostate cancer patients [Training cohort]

| PRJNA412693 | ENA

Urine miRNA transcriptome of prostate cancer patients

Project description:Urine miRNA transcriptome of prostate cancer patients

| PRJNA342023 | ENA

Screening of urine methylation biomarker for prostate cancer detection

Project description:Methylation profiling of urine samples from patients with aggressive prostate cancer and without prostate cancer. Methylated DNA was immunoprecipitated with anti-methylcytosine antibodies from genomic DNA and detected by Affymetrix CytoScanHD chips. Methylated DNA was purified by 5-mC antibodies and Affymetrix CytoScanHD arrays were performed according to the manufacturer's protocols.

2019-03-07 | E-MTAB-7732 | biostudies-arrayexpress

Discovery cohort for SET ER/PR

Project description:Discovery cohort for SET ER/PR

| PRJNA531709 | ENA

Genomic biomarkers from urine cells indicate a unique metabolomic difference between sepsis and sterile inflammation (discovery cohort)

Project description:Genomic biomarkers from urine cells indicate a unique metabolomic difference between sepsis and sterile inflammation (discovery cohort)

| PRJNA707447 | ENA

Detection of Aggressive Prostate Cancer-Associated Glycoproteins in Urine using Glycoproteomics and Mass Spectrometry

Project description:Clinical management of prostate cancer remains a significant challenge due to the lack of available tests for guiding treatment decisions. The blood Prostate-Specific Antigen (PSA) test has facilitated early detection and intervention of prostate cancer. However, blood PSA levels are less effective in distinguishing aggressive from indolent prostate cancers and other benign prostatic diseases. Thus, the development of novel approaches specific for prostate cancer that can differentiate aggressive from indolent disease remains an urgent medical need. In the current study, we evaluated urine specimens from prostate cancer patients instead of serum using liquid chromatography-tandem mass spectrometry (LC-MS/MS), with the aim of identifying effective prostate cancer biomarkers. Glycoproteins from urine samples of prostate cancer patients with different Gleason scores were characterized via solid phase extraction of N-linked glycosite-containing peptides and LC-MS/MS. In total, 2923 unique glycosite-containing peptides were identified. Comparison of urine-based glycoproteins with those identified from aggressive and non-aggressive prostate cancer tissues as well as sera from prostate cancer patients revealed that the majority of aggressive prostate cancer-associated glycoproteins were more readily detected in patient urine than serum samples. Our data collectively indicate that urine provides a highly reliable source for biomarker testing in patients with aggressive prostate cancer.

2022-02-28 | PXD004495 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data